News

Discover the latest advancements in CSU therapy, including Gil Yosipovitch's insights on barzolvolimab's promising results and its potential impact on patient care.

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

CURE spoke with experts about possible dermatologic adverse effects faced by patients with breast cancer.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

The Phoenix-based dermatologist encourages innovative and patient-tailored strategies to optimize pigment restoration.

Arcutis has expanded roflumilast cream in the US, a steroid-free treatment for mild to moderate AD in young children.

Updated FDA policies eliminate many comparative efficacy trials, reducing biosimilar development time and cost by relying more on analytical testing.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

Learn more about the in-depth topics covered in the October 2025 print issue of Dermatology Times.

Stephanie Alvarez, marketing director of Cognivia, details her experience with psoriasis and why she believes clinical trials should reflect more real-world patients and scenarios.

Avalo Therapeutics completes enrollment in the LOTUS trial for AVTX-009, targeting hidradenitis suppurativa with promising IL-1β inhibition.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Pennsylvania Dermatology Physician Assistants (PDPA) Keystone Dermatology Conference in Philadelphia, Pennsylvania.

At Fall Clinical 2025, Andrew Alexis, MD, reviewed topical, oral, and procedural interventions with patients with melasma and hyperpigmentation, especially in patients with skin of color.

In 2 replicate phase 3 trials, once-daily upadacitinib 15 mg significantly improved total and facial repigmentation in adults and adolescents with non-segmental vitiligo, with a safety profile consistent with prior indications.

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.

Indomo's ClearPen could revolutionize acne treatment with at-home microneedle injections, offering instant access to effective corticosteroid therapy for inflammatory lesions.

Chava Wald shares her inspiring journey with AD, advocating for patient empowerment and compassionate care during Eczema Awareness Month.

Catch up on coverage from the entire 2025 Fall Clinical Dermatology Conference held in Las Vegas, Nevada.

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, outline their long-term vision for the National Dermatology Leadership Summit, promoting collaboration and advocacy.

Explore the intricate relationship between rheumatologic dermatology and breast cancer, highlighting diagnostic challenges and treatment insights for dermatologists.

Join leading experts at the 2025 Inflammatory Skin Disease Summit to explore groundbreaking research and innovations in dermatologic care and therapies.

Incyte reveals promising TRuE-AD4 trial results for ruxolitinib cream, showcasing its effectiveness and safety for adults with moderate atopic dermatitis.

Explore the latest cosmetic trends for 2025, including artificial freckles, antiaging sunscreens, and IV NAD+ infusions, as discussed by Zoe Diana Draelos, MD.

According to a poster at Fall Clinical 2025, over 80% of patients remained flare-free across the 2-year period.

Explore a personal journey of resilience and proactive choices in the fight against breast cancer during Breast Cancer Awareness Month.

At Fall Clinical, new findings from the ENCOMPASS study revealed significant unmet needs in psoriasis care, highlighting a strong preference for effective oral therapies among patients and providers.

Quoin Pharmaceuticals' QRX003 granted FDA Orphan Drug Designation, advancing treatment for Netherton Syndrome, a rare dermatological disease.

Discover how the National Dermatology Leadership Summit will unite PAs and NPs to enhance collaboration, education, and advocacy in dermatology.

Bristol Myers Squibb reveals promising data on deucravacitinib's efficacy for psoriatic arthritis and systemic lupus erythematosus, highlighting its potential as a new treatment option.